Inves�ga�ng Chemotherapeu�c Resistance: Why is Glioblastoma So Deadly?
1

1

2

3

2

Anne C . Christensen, Thomas W. Cameron, Evan T. Meagher, A�que Ahmed, PhD., and Jonathon F. Mauser, PhD.
1. Winona State University Department of Biology 2. Winona State University Department of Chemistry 3. Feinberg School of Medicine, Northwestern University

Results

Abstract
Glioblastoma mul�forme (GBM), a malignancy of the glioblast stem cells of the brain, is one of the
most aggressive and untreated forms of brain cancer. When an individual is diagnosed with GBM, depending on the loca�on of the tumor, there are three treatment op�ons including surgery, radia�on,
chemotherapy or the combina�on of these treatments. Many pa�ents choose chemotherapy, however most GBM cases show li�le to no response to Temozolomide (TMZ), which is a common chemotherapy drug used for this type of cancer. In some recent studies, researchers have no�ced an elevated amount or over produc�on of an enzyme, Inosine 5'-monophosphate dehydrogenase (IMPDH).
This enzyme helps with DNA repair but in many GBM cases, due to its over produc�on, it repairs at
such a fast rate it does not allow TMZ to terminate the cancerous tumors. In our research we have
been inves�ga�ng whether the chemotherapeu�c agent causes the increase in expression directly or
whether it is a unique property of this cell type. Future direc�ons involve: determining a molecular
pathway that could lead to IMPDH expression at such high levels under chemotherapeu�c stress and
whether co-administering IMPDH inhibitors with TMZ can improve prognosis for those suﬀering from
GBM.

Experimental setup at each �mepoint:
Cells are washed, trypsinized and resuspended in cold PBS

Cells are spun down and chemically lysed

Conclusions
Cell lysate is incubated with assay reagents
for 2 hours at 37C & measured for protein
concentra�on. Absorbance of assay is read.

Based off the data collected, it was determined that TMZ has some sort of
influence on IMPDH activity levels. Simplistically looking at the kinetic
graphs, the longer exposure of TMZ the cells have, the more similar the
kinetic curves seem to be. Overall, the analyzed data collected was somewhat inconclusive but there are evident changes being seen. More trials
are being done and data is being analyzed to help develop a more conclusive understanding.

Future Directions

The future direction of the project includes optiizing our assay and
using different lines of GBM to determine enzyme activities in correlation to the cell line used for this project. In addition, there is
some interest in working with different types of cancer lines as well
as HeLa cells to see how the results would correlate. In addition,
some studies have shown that an IMPDH inhibitor drug, Mycophenolate Mofetil (MMF), has been approved as an anti-tumor effects in
solid and blood cancers of which could be used in our lab in a cocktail with TMZ and see the correlating effects on cell line proliferation

Introduction
Cancer is a disease of uncontrolled genera�on of cells based oﬀ the loss of func�on of tumor suppressor genes or gain of func�on of oncogenes. This disease can proliferate in any �ssues in the body,
including neural �ssues such as the brain of which is one of the most invasive types. Glioblastoma
mul�forme (GBM), a malignancy of the suppor�ng cells of the brain, is one of the most aggressive
forms of brain cancers. With a median survival of only 14.6 months, the bleak prognosis of GBM is a
result of the high rate of recurrence in pa�ents. (1,3) When an individual is diagnosed with GBM, depending on the loca�on of the tumor, there are three treatment op�ons. These include surgery, radia�on, chemotherapy or the combina�on of these treatments. If the pa�ent decides to go through
with chemotherapy for treatment; there is a high probability of intense damage done on the body in
response to the treatment. Usually this type of treatment has a well-received response by the shrinking or elimina�ng of the tumor all together depending on the case.
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Figure 2. According to the IMPDH specific activity data, around hour 48
there seems to be an increase in activity in response to TMZ treatment.
DMSO and TMZ treated have some correlation towards the end of collection. Going further with the project it was decided to run kinetic activity
assay in order to get a better understanding of what was happening during
the duration of the incubation.

Figure 3. According to another trial of the IMPDH specific data, around
hour 24 there seems to be an increase in activity in response to TMZ
treatment. DMSO and TMZ treated have some correlation towards the
end of collection.

TMZ treated U251 GBM cells do not appear to deviate from the control treatment overall but may exhibit spikes of ac�vity a�er treatment, which reverts to baseline
within 24 hours. We are currently working on determining why the �ming may vary based on our experimental condi�ons.

Problem: A 2 hour assay followed by an absorbance measurement doesn’t give us very good resolu�on on what is happening
in the assay during the incuba�on. Perhaps the assay doesn’t reveal the whole story in the way we are doing it.
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Figure 8. A. Mycophenolate, an IMPDH inhibitor
drug that could be co-treated with TMZ to
enhance prognosis and outcomes.
B. Mycophenolate blocks IMPDH activity, leading
to a defective de novo guanine synthesis pathway

Approach: Perform assay in microplate reader to determine what is happening in the assay in real-�me.

D

E

Patient has GBM and is
treated with TMZ

Increased activity results in cell proliferation
and any DNA damage TMZ has done to the
tumor has been reversed

The tumor is relatively unaffected
by the chemotherapy and continues
to metastasize
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TMZ tries to repress the tumor’s DNA
by methylating at guanine residues

IMPDH, the enzyme responsible for
synthesizing new guanine residues is
increased in activity

As exposure to TMZ is
increased, enzyme
activity would respond

Hypothesis

G
Seed Cells in SIM+FBS

Treat cells with TMZ (treatment) or
DMSO (control)

Harvest cells at 6, 24, 48, 96 hours post treatment and perform IMPDH assay
and Bradford assay to determine speciﬁc ac�vity of IMPDH as a func�on
of treatment �me

Figure 4. According to the absorbance activity, IMPDH in the TMZ
condition initially is at a high level but linearly decreases and plateaus around the same level as DMSO and the control by the end of
2 hours.

Figure 5. According to the absorbance activity, IMPDH activity for TMZ was
now seen initially at a lower level, jumping further along and then plateauing
around the same level as DMSO and the control by 2 hours elapsed time.

Figure 1. A. human brain aﬀected with glioblastoma mul�forme. An obvious tumor mass is observed. B-C. Human U251 GBM cell lines used in this study.
D. Temozolomide (TMZ) alkylates DNA on guanine residues and suppresses the ability for the DNA to divide, hal�ng the cancer. E. Common events in the
treatment of GBM with TMZ leading to our hypothesis that IMPDH increases speciﬁcally in reponse to TMZ treatment. F. Role oF IMPDH In purine
biosynthesus. G. Flowchart of experimenta�on to determine IMPDH ac�vity change during treatment

Based oﬀ this informa�on, some ques�ons we asked before to help lead our research was: What is causing escala�on in expression of this enzyme? Is this escala�on directly correla�ng in response to TMZ? If
so, is the increase in enzyme ac�vity dose dependent? If not, does this occur naturally in GBM cells and
is there a way to inhibit these enzymes while administering chemotherapy to make it more eﬀec�ve?
Figure 6. By 48 hours post-treatment, TMZ’s IMPDH activity is near
baseline levels compared to control and DMSO timepoints.

Figure 7. By 96 hours post-treatment, the DMSO and TMZ conditions are
indistiguishable, either implying that TMZ is used up or that the effect of
TMZ on IMPDH is completed
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